ATA Inc. Stock News

NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental heal

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disord

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorder

Whether you're into finances or just a fan of Shark Tank, chances are you know who Kevin O’Leary is. AKA Mr. Wonderful, the Canadian investor of Irish heritage is well known in the finance sp

DETROIT, March 4, 2022 /PRNewswire/ -- The Benzinga Psychedelics Advisory Council is a collective of the leading minds and voices in the psychedelics space, composed of key thought leaders sharing i

- Führende gemeinnützige und kommerzielle Organisationen der psychedelischen Wissenschaft teilen die Vision von der Heilung psychischer Erkrankungen

The psychedelics sector received its latest sign of acceptance from Wall Street with famed investor Cathie Wood taking a position in Atai Life Sciences (NASDAQ: ATAI) through her ARKG ETF. The country

Cathie Wood-led Ark Investment Management on Wednesday further lowered its exposure in Twitter Inc (NYSE: TWTR), a day before the microblogging company is scheduled to report its financial results for

The clinical-stage biopharmaceutical company benefited from an increased interest in companies working on psychedelic therapies.

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)

The Week In Psychedelics Last week saw some interesting developments from two of the largest publicly-traded companies in the psychedelics space: MindMed and Atai Life Sciences. MindMed announced that

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Atara To Sell Manufacturing Plant to Fuji's CDMO Unit For $100M Atara Biotherapeutics, Inc. (NASDAQ: A

ATAI Life Sciences (NASDAQ: ATAI) on Tuesday announced Invyxis, a new program to accelerate the company’s portfolio of compounds. What Happend: The clinical-stage biotechnology company focused on

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials.

New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) published encouraging data from a Phase II trial looking at ketamine-assisted ther